To further investigate the synergistic anti‐tumor effects of nanoparticles targeting FABP5 combined with RFA in vivo, mice were divided into four groups: RP (control), SRP, FRP, and FSRP, with the latter three serving as treatment groups (Figure6A). This evidence concerns the gene FABP5 and neoplasm.